68Ga-XACP3 PET/CT for detecting prostate cancer lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers will give participants contemporaneous 68Ga-XACP3 and standard 68Ga-PSMA PET/CT scans for initial staging, metastasis evaluation, or suspected recurrence. Tumor uptake will be measured quantitatively using SUVmax and lesions will be counted by visual interpretation on each scan. The diagnostic accuracy of 68Ga-XACP3 will be calculated and directly compared to the standard-of-care 68Ga-PSMA PET/CT. Results will show whether the new ACP3-targeting tracer identifies the same or additional lesions relative to PSMA imaging.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (aged 18 years or older);
* Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report);
* Patients who had scheduled both standard-of-care imaging (68Ga-PSMA PET/CT) and 68Ga-XACP3 PET/CT scans;
* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

* The inability or unwillingness of the research participant or legal representative to provide written informed consent.

Where it's running

• The First Affiliated Hospital of Xiamen University
  Xiamen, Fujian, China Recruiting

Study contacts

• Study coordinator: Liang Zhao
• Email: wzhaoliang01@163.com
• Phone: 86 18818350620

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing two PET imaging agents for prostate cancer diagnosis

  This study is testing a new PET imaging agent for prostate cancer to see if it works better than an existing one in diagnosing the disease and spotting any spread or recurrence.

  Recruiting Early Phase 1 Anhui Provincial Hospital · Hefei, Anhui · NCT06756334

• Registry assessing PSMA PET outcomes in prostate cancer

  This study is testing if PSMA PET imaging can help doctors better understand the outcomes for men with prostate cancer compared to traditional methods.

  Recruiting University Hospital, Essen · Essen · NCT06320223

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• 68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery

  This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885423

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.